Comparative Pharmacology
Head-to-head clinical analysis: ETRAFON FORTE versus TREMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAFON FORTE versus TREMIN.
ETRAFON-FORTE vs TREMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ETRAFON-FORTE is a combination of perphenazine (a phenothiazine antipsychotic) and amitriptyline (a tricyclic antidepressant). Perphenazine blocks postsynaptic dopamine D2 receptors in the mesolimbic system. Amitriptyline inhibits reuptake of serotonin and norepinephrine, enhancing neurotransmission. Additionally, amitriptyline blocks histamine H1, muscarinic, and alpha-adrenergic receptors.
Trihexyphenidyl is a centrally acting anticholinergic agent that blocks muscarinic acetylcholine receptors in the basal ganglia, restoring the balance between dopaminergic and cholinergic activity, thereby reducing extrapyramidal symptoms.
ETRAFON-FORTE (perphenazine 4 mg / amitriptyline 25 mg) oral tablets: 1 tablet three times daily or 1 tablet four times daily. Maximum daily dose: 4 tablets (perphenazine 16 mg / amitriptyline 100 mg).
1 mg orally 1-2 times daily, gradually increasing by 1 mg every 5-7 days up to 12 mg/day in divided doses. Maximum dose 12 mg/day.
None Documented
None Documented
Terminal elimination half-life of perphenazine: 8-12 hours; amitriptyline: 13-36 hours (mean ~20 hours). Steady-state achieved in 3-7 days. Clinical context: twice-daily dosing maintains therapeutic levels.
Terminal elimination half-life: 16 hours (range 12–20 hours) in adults, supporting twice-daily dosing; 35 hours in elderly patients
Primarily renal (approximately 70-80% as metabolites, <5% unchanged). Biliary/fecal elimination accounts for about 15-20% due to enterohepatic recirculation of metabolites.
Renal: 40% unchanged; fecal: 60% as metabolites
Category C
Category C
Antipsychotic/Antidepressant Combination
Antipsychotic